Catalent, Inc. (NYSE:CTLT) Receives Consensus Rating of “Hold” from Analysts
Shares of Catalent, Inc. (NYSE:CTLT – Get Free Report) have been given a consensus rating of “Hold” by the eight ratings firms that are presently covering the stock, MarketBeat reports. Eight ...
Catalent’s Biologics Underperformance and PCH Stability Lead to Hold Rating
Jefferies analyst David Windley maintained a Hold rating on Catalent (CTLT – Research Report) today and set a price target of $63.50.
BioSpace16h
Catalent Misses Fiscal Q1 Revenue Expectations as Pressure Mounts on Novo Holdings’ $16.5B Buyout
The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, ...
Catalent's Stock Gains Despite Q1 Earnings Miss, Gross Margin Up
CTLT's solid segmental results led to an encouraging fiscal first-quarter performance, driving share prices in after-hours ...
Business Insider1d
Catalent Inc. Reports Q1 Fiscal 2025 Results
Catalent Inc ( (CTLT)) has released its Q1 earnings. Here is a breakdown of the information Catalent Inc presented to its investors. Catalent Inc., a leading global contract development and ...
bovnews1d
How Does Catalent Inc (CTLT) Stack Up Against Its Industry Peers?
On Monday, Catalent Inc (CTLT) stock saw a decline, ending the day at $58.69 which represents a decrease of $-0.04 or -0.07% from the prior close of $58.73. The stock opened at $58.92 and touched a ...
Catalent Misses Q1 Revenue Estimates Ahead of $16.5 Billion Deal Close With Novo Holdings
Catalent's revenue for fiscal first quarter ended Sept. 30 was $1.02 billion, marginally below analysts' estimates of $1.06 ...
Catalent misses Q1 revenue estimates ahead of $16.5 bln deal close with Novo Holdings
Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.
Zacks.com on MSN1d
Catalent (CTLT) Reports Q1 Loss, Lags Revenue Estimates
Catalent (CTLT) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of $0.11. This compares to loss of $0.10 per share a year ago. These figures are adjusted for ...
Catalent reports Q1 loss, misses market expectations
Catalent (NYSE:CTLT), a contract development and manufacturing organization (CDMO), reported results for Q1 of fiscal 2025 that missed analyst expectations.
Catalent: Fiscal Q1 Earnings Snapshot
(CTLT) on Tuesday reported a loss of $129 million in its fiscal first quarter. The Somerset, New Jersey-based company said it had a loss of 71 cents per share. Losses, adjusted for one-time gains and ...
Novo Holdings planned $16.5B planned acquisitions of Catalent gets EU inquiry
Novo Holdings planned $16.5 billion purchase of Catalent (NYSE:CTLT) is being probed by the European antitrust regulator. The European Commission has set a date of Dec. 6 to decide if its analysis of ...